Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMS1YPZ)

Drug Name

SAR391786 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Muscle atrophy	FB32.Y	Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 8 (GDF-8)	TTSWPH8	GDF8_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Growth/differentiation factor 8 (GDF-8)	DTT	MSTN	-0.737	-1.737	1.433	-1.322

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Muscle atrophy

ICD Disease Classification

FB32.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Growth/differentiation factor 8 (GDF-8)	DTT	MSTN	1.64E-01	-0.06	-0.06

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01963598) Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia. U.S. National Institutes of Health.
2	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.